(Q38888365)

7 September 2017

1 reference

title

Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites (English)

1 reference

7 September 2017

Mitesh Patel

1

1 reference

7 September 2017

Kunal S Taskar

series ordinal

2

1 reference

7 September 2017

Maciej J Zamek-Gliszczynski

series ordinal

3

1 reference

7 September 2017

publication date

1 July 2016

1 reference

The Journal of Clinical Pharmacology

7 September 2017

published in

1 reference

7 September 2017

volume

56 Suppl 7

1 reference

7 September 2017

page(s)

S23-39

1 reference

Renal transporters in drug development

7 September 2017

cites work

1 reference

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios

21 January 2018

1 reference

Membrane transporters in drug development

21 January 2018

1 reference

Understanding the transport properties of metabolites: case studies and considerations for drug development.

21 January 2018

1 reference

Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites

21 January 2018

1 reference

Transporters as a determinant of drug clearance and tissue distribution

21 January 2018

1 reference

Organic anion transporting polypeptides (OATPs): regulation of expression and function.

21 January 2018

1 reference

Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions

21 January 2018

1 reference

Risk for myopathy with statin therapy in high-risk patients.

21 January 2018

1 reference

FDA adverse event reports on statin-associated rhabdomyolysis

21 January 2018

1 reference

Rhabdomyolysis and HMG-CoA reductase inhibitors

21 January 2018

1 reference

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

International Transporter Consortium commentary on clinically important transporter polymorphisms.

21 January 2018

1 reference

Impact of genetic variation in OATP transporters to drug disposition and response

21 January 2018

1 reference

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

21 January 2018

1 reference

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

21 January 2018

1 reference

Impact of OATP transporters on pharmacokinetics

21 January 2018

1 reference

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care

21 January 2018

1 reference

ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans

21 January 2018

1 reference

Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans

21 January 2018

1 reference

Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data

21 January 2018

1 reference

Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans

21 January 2018

1 reference

The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.

21 January 2018

1 reference

Kinetic Interpretation of the Importance of OATP1B3 and MRP2 in Docetaxel-Induced Hematopoietic Toxicity

21 January 2018

1 reference

Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia

21 January 2018

1 reference

Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics

21 January 2018

1 reference

Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex

21 January 2018

1 reference

Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption

21 January 2018

1 reference

Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein

21 January 2018

1 reference

Screening of OATP1B1/3 and OCT1 inhibitors in cryopreserved hepatocytes in suspension

21 January 2018

1 reference

Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms.

21 January 2018

1 reference

Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1.

21 January 2018

1 reference

Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins

21 January 2018

1 reference

OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.

21 January 2018

1 reference

Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide

21 January 2018

1 reference

OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies

21 January 2018

1 reference

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver

21 January 2018

1 reference

Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers

21 January 2018

1 reference

Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions

21 January 2018

1 reference

Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants.

21 January 2018

1 reference

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

21 January 2018

1 reference

Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines.

21 January 2018

1 reference

Novel liver-specific organic anion transporter OAT7 that operates the exchange of sulfate conjugates for short chain fatty acid butyrate

21 January 2018

1 reference

Isolation of a family of organic anion transporters from human liver and kidney

21 January 2018

1 reference

Identification of multispecific organic anion transporter 2 expressed predominantly in the liver

21 January 2018

1 reference

Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters

21 January 2018

1 reference

Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.

21 January 2018

1 reference

Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes

21 January 2018

1 reference

Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.

21 January 2018

1 reference

Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.

21 January 2018

1 reference

The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation

21 January 2018

1 reference

Emerging transporters of clinical importance: an update from the International Transporter Consortium

21 January 2018

1 reference

Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.

21 January 2018

1 reference

Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs.

21 January 2018

1 reference

Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane

21 January 2018

1 reference

Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis

21 January 2018

1 reference

Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers.

21 January 2018

1 reference

Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.

21 January 2018

1 reference

Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes

21 January 2018

1 reference

MRP6 (ABCC6) detection in normal human tissues and tumors.

21 January 2018

1 reference

P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide

21 January 2018

1 reference

Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception

21 January 2018

1 reference

OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids

21 January 2018

1 reference

Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver

21 January 2018

1 reference

Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.

21 January 2018

1 reference

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

21 January 2018

1 reference

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

21 January 2018

1 reference

Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

21 January 2018

1 reference

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.

21 January 2018

1 reference

Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.

21 January 2018

1 reference

Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report

21 January 2018

1 reference

Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation

21 January 2018

1 reference

Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.

21 January 2018

1 reference

UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients

21 January 2018

1 reference

Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans

21 January 2018

1 reference

The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia

21 January 2018

1 reference

The apical conjugate efflux pump ABCC2 (MRP2).

21 January 2018

1 reference

Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy

21 January 2018

1 reference

Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome)

21 January 2018

1 reference

Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin

21 January 2018

1 reference

Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11.

21 January 2018

1 reference

Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.

21 January 2018

1 reference

Clinical relevance of drug efflux pumps in the gut.

21 January 2018

1 reference

Importance of P-glycoprotein for drug-drug interactions

21 January 2018

1 reference

Transporters and drug-drug interactions: important determinants of drug disposition and effects

21 January 2018

1 reference

Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study

21 January 2018

1 reference

The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.

21 January 2018

1 reference

Clinical Pharmacokinetics of Metformin

21 January 2018

1 reference

Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4.

21 January 2018

1 reference

Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis

21 January 2018

1 reference

Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.

21 January 2018

1 reference

CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice

21 January 2018

1 reference

Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters

21 January 2018

1 reference

Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.

21 January 2018

1 reference

Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines

21 January 2018

1 reference

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport

21 January 2018

1 reference

PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me.

21 January 2018

1 reference

PET imaging of Oatp-mediated hepatobiliary transport of [(11)C] rosuvastatin in the rat.

21 January 2018

1 reference

Evaluation of Oatp and Mrp2 activities in hepatobiliary excretion using newly developed positron emission tomography tracer [11C]dehydropravastatin in rats

21 January 2018

1 reference

Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients

21 January 2018

1 reference

Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients

21 January 2018

1 reference

Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.

21 January 2018

1 reference

Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus

21 January 2018

1 reference

Cyclosporine markedly raises the plasma concentrations of repaglinide

21 January 2018

1 reference

Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease

21 January 2018

1 reference

Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism

21 January 2018

1 reference

Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin

21 January 2018

1 reference

Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin

21 January 2018

1 reference

Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.

21 January 2018

1 reference

Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects

21 January 2018

1 reference

effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers

21 January 2018

1 reference

Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin

21 January 2018

1 reference

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

21 January 2018

1 reference

Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin

21 January 2018

1 reference

Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin

21 January 2018

1 reference

The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers

21 January 2018

1 reference

Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

21 January 2018

1 reference

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

21 January 2018

1 reference

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

21 January 2018

1 reference

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin

21 January 2018

1 reference

Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCPH.671

1 reference

7 September 2017

1 reference